For Immediate Release February 25, 2022
Montreal, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (NASDAQ: “SBFM” and
SBFMW) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the
research, development and commercialization of oncology and antiviral drugs today announced
that it has entered into an agreement with the University of Arizona for the purposes of advancing
the development of novel PLpro inhibitors discovered by the University of Arizona and the University of
Illinois Chicago researchers. The development of the Company’s lead PLpro inhibitor, SBFMPL4,
is currently continuing at the University of Georgia. At the University of Arizona, the research
effort will focus on determining the in vivo safety, pharmacokinetics, and dose selection properties
of 3 universities owned PLpro inhibitors followed by efficacy testing in MA10 mice infected with
SARS-CoV-2. Molecules showing efficacy in infected mice will be advanced to human trials.
“We are delighted to be working with the University of Arizona Coronavirus research team led by
Dr. Gregory Thatcher as well as the commercialization team at Tech Launch Arizona,” said Dr.
Steve Slilaty, CEO of Sunshine Biopharma. “It is of paramount importance to find a wide array of
inhibitors for PLpro, as this virus encoded protease is responsible for the suppression of the human
immune system, thereby enabling the virus to cause severe illness,” he added.
About the University of Arizona
The University of Arizona, a land-grant university with two independently accredited medical
schools, is one of the nation’s top 50 public universities, according to U.S. News & World Report.
Established in 1885, the university is widely recognized as a student-centric university and has
been designated as a Hispanic Serving Institution by the U.S. Department of Education. The
university ranked in the top 20 in 2019 in research expenditures among all public universities,
according to the National Science Foundation, and is a leading Research 1 institution with $734
million in annual research expenditures. The university advances the frontiers of interdisciplinary
scholarship and entrepreneurial partnerships as a member of the Association of American
Universities, the 66 leading public and private research universities in the U.S. It benefits the state
with an estimated economic impact of $4.1 billion annually.
About Tech Launch Arizona
Tech Launch Arizona is the office of the University of Arizona that creates social and economic
impact through commercializing inventions stemming from university research. The office builds
connections between talented UA faculty, researchers and staff and experienced entrepreneurs
and investors, to create an ecosystem that refines ideas that start in research and innovation
and grows them into products and businesses that benefit society. TLA supports entrepreneurship
through a variety of initiatives, including training startup teams in customer discovery, providing
funding to advance early-stage inventions toward market readiness, and hosting challenges to
help students and faculty move innovative ideas from concept to societal impact. In FY2021, TLA
took in 274 invention disclosures, had 100 U.S. patents issued, and executed 124 licenses and
options for UArizona technologies. The university has launched more than 100 startups since the
office was founded in 2012.
About Sunshine Biopharma
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date
have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells,
including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine
Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at
McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is the owner
of all patents and intellectual property pertaining to Adva-27a.
Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements that are based on current expectations, forecasts, and
assumptions of Sunshine Biopharma, Inc. (the “Company”) that involve risks as well as uncertainties that could cause
actual outcomes and results to differ materially from those anticipated or expected. These statements appear in a
number of places in this release and include all statements that are not statements of historical fact regarding the
intent, belief or current expectations of the Company, including statements related to the Company’s drug
development activities, financial performance, and future growth. These risks and uncertainties are further described
in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and
the timing of certain events could differ materially from those projected in or contemplated by the forward-looking
statements due to a number of factors detailed from time to time in the Company’s filings with the SEC. Reference is
hereby made to cautionary statements and risk factors set forth in the Company’s most recent SEC filings.
For Additional Information:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com